TLR4 and synovial sarcoma: By identifying the cell population and a signaling pathway responsible for the LAMP3/HSP70/BMP6 axis of connection, other therapeutic molecules that block lysosomal exocytosis, TLR4 activation, and/or induction of monocytes may be identified that can reverse the development of SS.